{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_name": "neladalkib"
  },
  "asset": {
    "name": "neladalkib",
    "ticker": "NUVL",
    "company": "Nuvalent",
    "modality": "Small molecule kinase inhibitor",
    "stage": "Phase 2 (NDA planned 1H 2026)",
    "one_liner": "Best-in-class ALK inhibitor with TRK-sparing selectivity designed to overcome lorlatinib resistance",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "ALK",
    "full_name": "Anaplastic Lymphoma Kinase",
    "class": "Receptor Tyrosine Kinase",
    "pathway": "ALK fusion (EML4-ALK) → constitutive kinase activation → tumor growth",
    "biology": {
      "simple_explanation": "ALK is a receptor tyrosine kinase that when fused to partner genes like EML4 creates oncogenic fusion proteins driving tumor growth. ALK fusions occur in 3-5% of NSCLC, typically in younger patients with significant impact on quality of life.",
      "prevalence": "3-5% of NSCLC",
      "patient_demographics": "Often younger patients; significant impact on quality of life",
      "cns_involvement": "30-40% present with brain metastases; ~50% develop brain mets over disease course"
    },
    "resistance_mutations": {
      "primary_mutation": "G1202R (most common resistance mutation to 2nd-gen ALK TKIs)",
      "compound_mutations": "Increasingly common after lorlatinib; single agent often insufficient",
      "key_mutations": ["G1202R", "L1196M", "G1269A", "I1171T/N/S", "F1174C/L", "L1198F"]
    },
    "why_good_target": {
      "clinical_validation": "Multiple approved ALK TKIs with excellent outcomes in 1L (lorlatinib mPFS not reached at 60 months)",
      "unmet_need": [
        "60% of patients progress on 2L lorlatinib within 24 months",
        "Compound mutations emerge after lorlatinib with limited treatment options",
        "TRK-related toxicity with current ALK TKIs"
      ]
    }
  },
  "indications": {
    "lead": {
      "name": "ALK+ NSCLC (TKI pre-treated)",
      "stage": "Phase 2 pivotal (NDA planned 1H 2026)",
      "rationale": "High unmet need in patients progressing on lorlatinib and other ALK TKIs"
    },
    "expansion": [
      {
        "name": "ALK+ NSCLC (TKI-naïve)",
        "stage": "Phase 3 ALKAZAR enrolling",
        "rationale": "Potential to compete with lorlatinib in frontline setting"
      },
      {
        "name": "ALK+ solid tumors (non-NSCLC)",
        "stage": "Phase 2 ongoing",
        "rationale": "ALK fusions in IMT, neuroblastoma, and other cancers"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "ALKOVE-1 (NCT05384626)",
    "trial_design": {
      "phase": "Phase 1/2",
      "design": "Global open-label multi-cohort study",
      "enrollment": "781 patients enrolled"
    },
    "populations": {
      "tki_pretreated_pivotal": {
        "n": 253,
        "description": "ALK+ NSCLC with ≥1 prior ALK TKI, data cutoff Aug 29, 2025"
      },
      "lorlatinib_naive": {
        "n": 63,
        "description": "Subset without prior lorlatinib"
      },
      "lorlatinib_experienced": {
        "n": 190,
        "description": "Subset with prior lorlatinib"
      },
      "tki_naive_exploratory": {
        "n": 44,
        "description": "TKI-naïve patients (exploratory)"
      },
      "alk_solid_tumors": {
        "n": 34,
        "description": "Non-NSCLC ALK+ solid tumors"
      }
    },
    "tki_pretreated_results": {
      "data_cutoff": "August 29, 2025",
      "orr_overall": "31% (n=253)",
      "orr_g1202r_mutation": "68%",
      "orr_compound_mutations": "58% (n=43)",
      "orr_lorlatinib_naive": "46% (n=63)",
      "orr_lorlatinib_experienced": "26% (n=190)",
      "dor_overall": "76% ≥6mo, 64% ≥12mo, 53% ≥18mo",
      "dor_lorlatinib_naive": "89% ≥6mo, 80% ≥12mo",
      "dor_lorlatinib_experienced": "median 17.6 months",
      "dor_compound_mutations": "69% ≥12mo",
      "intracranial_orr_overall": "32%",
      "intracranial_orr_lorlatinib_naive": "63%"
    },
    "tki_naive_results": {
      "data_cutoff": "August 29, 2025 (exploratory)",
      "orr": "86% (n=44)",
      "dor": "91% ≥6 months and ≥12 months",
      "intracranial_orr": "78%",
      "intracranial_cr": "4 patients"
    },
    "alk_solid_tumor_results": {
      "orr_tki_naive": "69% (9/13)",
      "orr_tki_pretreated": "29% (6/21)",
      "tumor_types": "IMT, neuroblastoma, sarcoma, peritoneal mesothelioma, RCC, CRC"
    },
    "safety": {
      "discontinuation_rate": "5%",
      "dose_reduction_rate": "17%",
      "alt_elevation": "47% any grade (20% Gr3+)",
      "ast_elevation": "44% any grade (16% Gr3+)",
      "transaminase_note": "Asymptomatic and reversible",
      "key_differentiator": "TRK-sparing design (>20x selectivity ALK vs TRKB)"
    }
  },
  "ongoing_trials": [
    {
      "trial_name": "ALKAZAR",
      "phase": "Phase 3",
      "design": "Head-to-head vs alectinib in TKI-naïve ALK+ NSCLC",
      "enrollment": "~450 patients",
      "status": "Enrolling"
    }
  ],
  "mechanism_differentiation": {
    "trk_sparing": {
      "selectivity_alk_vs_trkb": ">20x",
      "clinical_relevance": "Avoids CNS toxicity (cognitive effects, mood changes) seen with lorlatinib"
    },
    "mutation_coverage": {
      "single_mutations": "IC50 0.1-30 nM across key mutations",
      "compound_mutations": "Active against compound mutations that confer lorlatinib resistance"
    },
    "cns_penetration": {
      "kpuu": "~0.4 (similar to lorlatinib)",
      "clinical_evidence": "32-63% intracranial ORR depending on prior therapy"
    }
  },
  "catalysts": [
    {
      "event": "NDA submission",
      "timing": "1H 2026",
      "importance": "critical",
      "what_to_watch": "FDA acceptance and review timeline"
    },
    {
      "event": "ALKAZAR Phase 3 enrollment completion",
      "timing": "2026",
      "importance": "high",
      "what_to_watch": "Enrollment pace for 1L head-to-head vs alectinib"
    }
  ],
  "competitive_landscape": {
    "approved_alk_tkis": [
      {
        "drug": "lorlatinib",
        "company": "Pfizer",
        "position": "Current 1L standard; mPFS not reached at 60 months",
        "limitation": "Compound mutations emerge; CNS toxicity (cognitive effects 21%)"
      },
      {
        "drug": "alectinib",
        "company": "Roche",
        "position": "Prior 1L standard of care",
        "limitation": "Inferior to lorlatinib in 1L; limited mutation coverage"
      },
      {
        "drug": "brigatinib",
        "company": "Takeda",
        "limitation": "Inferior to lorlatinib; limited compound mutation activity"
      }
    ],
    "neladalkib_advantages": [
      "Active against lorlatinib-resistant compound mutations (58% ORR)",
      "TRK-sparing selectivity (>20x ALK vs TRKB)",
      "Strong CNS activity comparable to lorlatinib",
      "Only option for post-lorlatinib patients with compound mutations"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "High for accelerated approval in TKI pre-treated",
    "peak_sales_estimate": "$1.35B-$2.0B US with frontline expansion",
    "key_risks": [
      "Lorlatinib's dominant 1L position (mPFS not reached at 60 mo)",
      "ALKAZAR Phase 3 execution and enrollment",
      "Transaminase elevations may limit some patients"
    ]
  },
  "market_opportunity": {
    "us_alk_patients": "~9,000 annually",
    "global_alk_patients": "30,000-45,000 annually",
    "us_peak_sales": "$1.35B-$2.0B",
    "key_insight": "Larger market than ROS1 with higher peak sales potential"
  }
}
